了解使用治疗注意力缺陷多动障碍药物对身体生长和心血管功能的风险。
Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function.
作者信息
Vitiello Benedetto
机构信息
Child and Adolescent Treatment and Preventive Intervention Research Branch, Division of Services and Intervention Research, National Institute of Mental Health, Room 7147, 6001 Executive Boulevard, Bethesda, MD 20892-9633, USA.
出版信息
Child Adolesc Psychiatr Clin N Am. 2008 Apr;17(2):459-74, xi. doi: 10.1016/j.chc.2007.11.010.
Abstract
The effects of stimulant medications and atomoxetine on physical growth and on cardiovascular function are reviewed in light of the most recent data, with attention to clinical implications and research needs. Although these medications have a favorable benefit/risk profile and do not induce clinically significant changes in growth or cardiovascular function in the majority of cases, careful patient monitoring is needed to identify individuals at risk for negative outcomes. More research is needed to elucidate the mechanism of growth suppression to estimate better the risk for rare but life-threatening events and test the effectiveness of monitoring procedures.
摘要
根据最新数据，对兴奋剂类药物和托莫西汀对身体生长及心血管功能的影响进行了综述，并关注其临床意义和研究需求。尽管这些药物具有良好的效益/风险比，且在大多数情况下不会引起生长或心血管功能的临床显著变化，但仍需要对患者进行仔细监测，以识别有出现不良后果风险的个体。需要开展更多研究来阐明生长抑制的机制，以便更好地估计罕见但危及生命事件的风险，并测试监测程序的有效性。
相似文献
1
Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function.
Child Adolesc Psychiatr Clin N Am. 2008 Apr;17(2):459-74, xi. doi: 10.1016/j.chc.2007.11.010.
2
Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.
Drug Saf. 2010 Oct 1;33(10):821-42. doi: 10.2165/11536380-000000000-00000.
3
Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.
J Child Adolesc Psychopharmacol. 2012 Dec;22(6):423-431. doi: 10.1089/cap.2012.0014.
4
Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Clin Ther. 2007 Jun;29(6):1168-77. doi: 10.1016/j.clinthera.2007.06.017.
5
[Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].
Arch Pediatr. 2014 Jan;21(1):108-12. doi: 10.1016/j.arcped.2013.11.001. Epub 2013 Dec 3.
6
Methylphenidate and atomoxetine treatment negatively affect physical growth indexes of school-age children and adolescents with attention-deficit/hyperactivity disorder.
Pharmacol Biochem Behav. 2021 Sep;208:173225. doi: 10.1016/j.pbb.2021.173225. Epub 2021 Jul 1.
7
ADHD update: new data on the risks of medication.
Harv Ment Health Lett. 2006 Oct;23(4):3-5.
8
An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics.
J Child Adolesc Psychopharmacol. 2009 Oct;19(5):493-9. doi: 10.1089/cap.2008.0126.
9
Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
CNS Drugs. 2017 Mar;31(3):199-215. doi: 10.1007/s40263-017-0410-7.
10
Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database.
Drug Saf. 2009;32(11):1089-96. doi: 10.2165/11317630-000000000-00000.
引用本文的文献
1
Narcolepsy: Beyond the Classic Pentad.
CNS Drugs. 2025 Mar;39(Suppl 1):9-22. doi: 10.1007/s40263-024-01141-9. Epub 2025 Mar 20.
2
Comparison of Insomnia, Depression, and Perceived Social Support among Individuals with Amphetamine Use Disorder (AUD) and Healthy Controls.
Alpha Psychiatry. 2025 Feb 28;26(1):38786. doi: 10.31083/AP38786. eCollection 2025 Feb.
3
Improving cognitive function in Chinese children with ADHD and/or RD through computerized working memory training.
BMC Psychol. 2024 Oct 18;12(1):574. doi: 10.1186/s40359-024-02065-1.
4
The Impact of Stimulant Medications on Blood Pressure and Body Mass Index in Children with Attention Deficit Hyperactivity Disorder.
Acad Pediatr. 2024 Apr;24(3):424-432. doi: 10.1016/j.acap.2023.08.018. Epub 2023 Aug 29.
5
Consequences of Acute or Chronic Methylphenidate Exposure Using Ex Vivo Neurochemistry and In Vivo Electrophysiology in the Prefrontal Cortex and Striatum of Rats.
Int J Mol Sci. 2022 Aug 2;23(15):8588. doi: 10.3390/ijms23158588.
6
Impact of CNS Stimulants for Attention-Deficit/Hyperactivity Disorder on Growth: Epidemiology and Approaches to Management in Children and Adolescents.
CNS Drugs. 2021 Aug;35(8):839-859. doi: 10.1007/s40263-021-00841-w. Epub 2021 Jul 23.
7
Diagnosis and Treatment Options for Preschoolers with Attention-Deficit/Hyperactivity Disorder.
J Child Adolesc Psychopharmacol. 2020 Mar;30(2):104-118. doi: 10.1089/cap.2019.0116. Epub 2020 Jan 20.
8
Prediction of sleep side effects following methylphenidate treatment in ADHD youth.
Neuroimage Clin. 2020;26:102030. doi: 10.1016/j.nicl.2019.102030. Epub 2019 Oct 21.
9
Increased arterial pressure in mice with overexpression of the ADHD candidate gene calcyon in forebrain.
PLoS One. 2019 Feb 12;14(2):e0211903. doi: 10.1371/journal.pone.0211903. eCollection 2019.
10
Effects of Atomoxetine on Height and Weight in Korean Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Retrospective Chart Review.
Psychiatry Investig. 2018 Jun;15(6):649-654. doi: 10.30773/pi.2018.02.25.1. Epub 2018 Jun 21.
本文引用的文献
1
Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS).
J Child Adolesc Psychopharmacol. 2007 Oct;17(5):593-604. doi: 10.1089/cap.2007.0058.
2
Effects of stimulant medication on growth rates across 3 years in the MTA follow-up.
J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):1015-1027. doi: 10.1097/chi.0b013e3180686d7e.
3
Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.
Psychopharmacology (Berl). 2007 Oct;194(2):197-209. doi: 10.1007/s00213-007-0840-x. Epub 2007 Jun 16.
4
The global market for ADHD medications.
Health Aff (Millwood). 2007 Mar-Apr;26(2):450-7. doi: 10.1377/hlthaff.26.2.450.
5
Effects of stimulants on Hispanic boys' height and weight.
J Am Acad Child Adolesc Psychiatry. 2007 Feb;46(2):150-1. doi: 10.1097/01.chi.0000246063.55082.95.
6
Safety and tolerability of methylphenidate in preschool children with ADHD.
J Am Acad Child Adolesc Psychiatry. 2006 Nov;45(11):1294-1303. doi: 10.1097/01.chi.0000235082.63156.27.
7
Stimulant-related reductions of growth rates in the PATS.
J Am Acad Child Adolesc Psychiatry. 2006 Nov;45(11):1304-1313. doi: 10.1097/01.chi.0000235075.25038.5a.
8
Stimulants and sudden death: what is a physician to do?
Pediatrics. 2006 Sep;118(3):1215-9. doi: 10.1542/peds.2006-0942.
9
Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder.
Biol Psychiatry. 2007 Mar 1;61(5):706-12. doi: 10.1016/j.biopsych.2006.05.002. Epub 2006 Aug 8.
10
Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder.
J Am Acad Child Adolesc Psychiatry. 2006 Aug;45(8):919-927. doi: 10.1097/01.chi.0000222788.34229.68.
Zotero 插件